依达拉奉联合阿替普酶治疗急性脑梗死效果观察

Clinical observation of the effect of edaravone combined with alteplase on acute cerebral infarction

目的探讨依达拉奉联合阿替普酶治疗急性脑梗死的临床疗效。方法将我院2012—2013年神经内科收治的70例急性脑梗死患者分为观察组及对照组各35例,2组患者均采用阿替普酶抗凝治疗,观察组患者加用依达拉奉治疗,采用NIHSS量表对患者治疗前后神经功能缺损情况进行评价,同时测定患者血清IL-6和hs-CRP水平。结果观察组患者治疗后血清IL-6和hs-CRP水平明显降低,2组比较差异有统计学意义(P<0.05);2组患者NIHSS评分均降低,观察组降低明显,差异有统计学意义(P<0.05)。结论依达拉奉联合阿替普酶治疗急性脑梗死,可降低血清IL-6和hs-CRP含量,改善患者神经功能,效果满意,值得临床推广。

Objective To investigate the clinical efficacy of edaravone alteplase treatment of acute cerebral infarc-tion.Methods Seventy patients with acute cerebral infarction in our hospital in 2012 -2013 admitted into observation group and control group ,35 cases ,two patients were treated with alteplase anticoagulant therapy ,the observation group were added with edaravone treatment ,the use of NIHSS scale of neurological deficit before and after treatment to evaluate the situation , the simultaneous determination of serum IL-6 and hs-CRP levels.Results The patients were observed after treatment of serum IL-6 and hs-CRP levels were significantly lower ,the difference was statistically significant （P〈 0.05）;groups of patients NIHSS scores were reduced significantly lower in patients in the observation group ,the difference was statistical significance （P〈0.05）.Conclusion Edaravone combined alteplase treatment of acute cerebral infarction ,can reduce serum IL-6 and hs-CRP levels and improve neurological function in patients with satisfactory results ,it is worth in clinical practice.